Researchers generate red blood cell-like cells from canine iPSCs

Researchers at Osaka Metropolitan University have made a significant leap in regenerative medicine by generating red blood cell-like cells from canine induced pluripotent stem cells (iPSCs), a breakthrough that could reshape veterinary care and inform human medical applications. The study, led by Professor Shingo Hatoya, builds on years of work to refine iPSC technology, addressing longstanding challenges in blood cell production and transplantation.

The team’s approach involved culturing canine iPSCs in conditions that mimic natural blood cell development. By inducing these cells to form clusters, they observed the emergence of progenitor cells capable of producing hemoglobin, the oxygen-carrying protein central to red blood function. A key innovation was the use of CRISPR-Cas9 genome editing to tag glycophorin A (GYPA), a critical red blood cell marker, with a fluorescent protein. This allowed real-time tracking of differentiation, revealing that over 96% of cells expressed GYPA under optimized conditions. However, only 3% of the cells underwent enucleation, a defining feature of mature red blood cells, highlighting the gap between laboratory results and clinical viability.

The research leverages collaborations with industry partners like TOKIWA-Bio Inc., which provided the canine iPSCs used in the study. Funding from Japan’s Science and Technology Agency and other institutions underscores the project’s interdisciplinary scope. While the cells generated are not yet suitable for transfusion, the methodology establishes a platform for further refinement. Hatoya emphasized that future work will focus on enhancing enucleation rates and understanding variability among cell lines, which could unlock new therapeutic avenues.

This achievement aligns with broader advancements in iPSC research, including methods to derive these cells from less invasive sources. A 2025 study published in *PLOS One* demonstrated the successful generation of virus-free canine iPSCs from umbilical cord tissue, a technique that could reduce animal stress during cell collection. Meanwhile, research from Cornell University’s Riney Canine Health Center highlights the potential of iPSCs to advance regenerative therapies for both dogs and humans, noting that stem cell technologies developed for veterinary medicine often have cross-disciplinary applications.

The work also contributes to the growing field of feeder-free iPSC cultivation, a method that eliminates the need for animal-derived support cells. A 2026 study in *Stem Cells Translational Medicine* detailed a feeder-free system for maintaining canine iPSCs, a step toward scalable, ethically sound production. This aligns with efforts to develop clinical-grade iPSCs, which could eventually be used to create personalized blood products for both veterinary and human patients.

Despite these advances, challenges remain. The low enucleation rate in the current study reflects the complexity of red blood cell maturation, a process that requires precise control over cellular signaling pathways. Researchers are also investigating how genetic differences among iPSC lines affect their differentiation potential, a factor that could influence the consistency of future therapies. As Hatoya noted, “Understanding these variations is critical for translating laboratory success into real-world applications.”

The study’s publication in *Stem Cells Translational Medicine* highlights its significance. By bridging gaps in veterinary and human medicine, the research underscores the potential of iPSCs to address pressing healthcare needs. As scientists refine these techniques, the prospect of lab-grown blood cells for dogs—and by extension, humans—moves closer to reality.